|
| Maintaining higher dose at follow-up visit |
| Dose escalation at follow-up visit |
| ||
|
| Fesoterodine 156 | Solifenacin 48 | p value | Fesoterodine 194 | Solifenacin 134 | p value |
| ICG-S, mean (SD) | 2.2 (1.2) | 2.9 (1.3) | 0.002 | 2.7 (1.4) | 3.1 (1.2) | 0.002 |
| ICG-I, mean (SD) | 1.9 (1.0) | 2.3 (1.2) | 0.040 | 2.0 (0.9) | 2.4 (1.0) | <0.001 |
| TBS, n (%) |
|
| 0.015 |
|
| 0.002 |
| Improved | 143 (91.6) | 37 (77.1) |
| 177 (91.2) | 112 (83.5) |
|
| No change | 11 (7.1) | 10 (20.8) |
| 17 (8.8) | 21 (15.7) |
|
| Impaired | 2 (1.3) | 1 (2.1) |
| 0 (0.0) | 1 (0.7) |
|
| OAB-q, mean (SD) |
|
|
|
|
|
|
| Symptom bother | 26.8 (18.4) | 36.1 (22.7) | 0.014 | 32.4 (20.2) | 38.9 (20.4) | 0.003 |
| Total HRQL | 75. 4 (17.7) | 67.5 (20.6) | 0.027 | 70.2 (18.9) | 66.3 (19.7) | NS |
| PPBC, mean (SD) | 1.7 (1.2) | 2.2 (1.3) | 0.041 | 2.1 (1.2) | 2.4 (1.1) | 0.017 |
| UPS, n (%) |
|
| NS |
|
| NS |
| Not able to hold urine | 19 (12.2) | 11 (22.9) |
| 36 (18.6) | 33 (24.6) |
|
| Able to hold urine until I reach the toilet if I go immediately | 78 (50.0) | 26 (54.2) |
| 112 (57.7) | 78 (58.2) |
|
| Able to finish what I am doing before going to the toilet | 59 (37.8) | 11 (22.9) |
| 46 (23.7) | 23 (17.2) |
|
| Morisky-Green, compliant, n (%) | 97 (62.2) | 24 (50.0) | NS | 88 (45.4) | 59 (44.0) | NS |
| Healthcare resources, mean (SD) | ||||||
| *Absorbent reduction | −1.2 | −0.5 | 0.011 | −1.4 | −1.2 | NS |
| Primary care visits | 1.8 (3.1) | 2.3 (2.9) | NS | 2.4 (2.8) | 2.4 (3.5) | NS |
| Specialist visits | 2.4 (1.6) | 3.4 (3.0) | NS | 2.6 (1.8) | 3.4 (3.7) | NS |